Christopher Carreras
27Patents
6h-index
31Co-inventors
69Inventor score
Filing activity: Feb 15, 2001 → Apr 1, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6562795B2 | Motilide compounds | Human Necessities | 19 | Expired |
| US8815910B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 7 | Active |
| US8815908B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 7 | Active |
| US8809339B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 7 | Active |
| US9408840B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | Emerging Cross-Sectional Technologies | 6 | Active |
| US7211568B2 | 9-Desoxoerythromycin compounds as prokinetic agents | Human Necessities | 6 | Expired |
| US8916569B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 5 | Active |
| US10272079B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | Human Necessities | 5 | Active |
| US8541448B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 4 | Active |
| US10376481B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Human Necessities | 3 | Active |
| US6875576B2 | Method for evaluating therapeutic efficacy | Physics | 3 | Expired |
| US6946482B2 | Motilide compounds | Chemistry; Metallurgy | 3 | Expired |
| US10543207B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 3 | Active |
| US8969377B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 2 | Active |
| US6750205B2 | Motilide compounds | Human Necessities | 2 | Expired |
| US10385024B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 2 | Active |
| US11318129B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 1 | Active |
| US9006281B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 1 | Active |
| US10940146B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | Human Necessities | 1 | Active |
| US11813304B2 | Compounds and methods for inhibiting phosphate transport | Physics | 0 | Active |
| US9289429B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 0 | Active |
| US9301951B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 0 | Active |
| US7407941B2 | N-desmethyl-N-substituted-11-deoxyerythromycin compounds | Human Necessities | 0 | Expired |
| US9289430B2 | Compounds and methods for inhibiting phosphate transport | Chemistry; Metallurgy | 0 | Active |
| US12016856B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.